D. Bitar, O. Lortholary, F. Dromer, B. Coignard, and C. D. , Mycoses invasives en France métropolitaine, PMSI 2001-2010 : incidence, létalité et tendances, pp.109-123, 2013.

L. Pagano, M. Caira, A. Candoni, M. Offidani, L. Fianchi et al., The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study, Haematologica. août, vol.91, issue.8, pp.1068-75, 2006.

D. P. Kontoyiannis, K. A. Marr, B. J. Park, B. D. Alexander, E. J. Anaissie et al., Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database, vol.50, pp.1091-100, 2001.

O. Lortholary, J. Gangneux, K. Sitbon, B. Lebeau, A. Thiébaut et al., Épidémiologie de l'aspergillose invasive en France : résultat du réseau SAIF, pp.121-125, 2005.

M. G. Schuster, A. A. Cleveland, E. R. Dubberke, C. A. Kauffman, R. K. Avery et al., Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study, Open Forum Infect Dis, vol.4, issue.2, pp.1-7, 2017.

C. Girmenia, A. M. Raiola, A. Piciocchi, A. Algarotti, M. Stanzani et al., Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. juin, vol.20, issue.6, pp.872-80, 2014.

C. Renaudat, K. Sitbon, M. Desnos-ollivier, A. Fontanet, S. Bretagne et al., Candidémies en Île-de-France : données de l'Observatoire des levures, pp.125-133, 2002.

L. Pagano, A. Busca, A. Candoni, C. Cattaneo, S. Cesaro et al., Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations, Blood Rev. mars, vol.31, issue.2, pp.17-29, 2017.

A. L. Colombo, J. N. De-almeida-júnior, M. A. Slavin, S. Chen, and T. C. Sorrell, Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer, Lancet Infect Dis. 31 juill, pp.1-13, 2017.

J. Gangneux and A. Drogoul, Infections fongiques invasives : nouvelles données épidémiologiques et écologiques. Hématologie. 1 août, vol.14, pp.5-11, 2008.

R. Courseau, C. Ourghanlian, D. Sismeiro, and L. M. Infectiologie,

, Association française des enseignants de parasitologie et mycologie. Parasitoses et mycosesElibrary France, 2016.

D. Sur,

C. Cordonnier and R. Herbrecht, Infections en hématologie

B. Sendid, Actualités sur l'épidémiologie et le diagnostic des infections fongiques invasives, Option/Bio. 1 janv, vol.28, issue.555, pp.13-18, 2017.

A. Johnson, TUP1 sequences from Candida albicans and methods for screening agents for inhibiting virulence in Candida albicans using TUP1, 1997.

M. Vaubourdolle, A. Collignon, and . Enseignante-en-pharmacie,

D. Sur,

B. De-pauw, T. J. Walsh, J. P. Donnelly, D. A. Stevens, J. E. Edwards et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 juin, vol.46, issue.12, pp.1813-1834, 2008.

B. Achour, A. Achour, H. Regaieg, H. Zaghouani, S. Majdoub et al., Aspergillose cérébrale en hématologie : apport de l'imagerie. À propos de deux cas, J Neuroradiol. 1 mars, vol.41, issue.1, p.28, 2014.

U. Cancer and . Environnement, Hémopathies malignes : cancer du sang, causes et risques, Cancer Environnement, 2016.

, Société canadienne du cancer. Qu'est-ce que la leucémie aiguë myéloblastique ?

H. Guiot, W. E. Fibbe, V. Wout, and W. , Risk Factors for Fungal Infection in Patients with Malignant Hematologic Disorders: Implications for Empirical Therapy and Prophylaxis, Clin Infect Dis. 1 avr, vol.18, issue.4, pp.525-557, 1994.

M. Territo, D. Geffen, . Neutropénie--hématologie, and . Oncologie, Édition professionnelle du Manuel Merck, 2018.

L. Pagano, M. Caira, A. Candoni, M. Offidani, B. Martino et al., Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study, Haematologica. avr, vol.95, issue.4, pp.644-50, 2010.

A. S. Omrani and R. S. Almaghrabi, Complications of hematopoietic stem transplantation: Fungal infections, Hematol Oncol Stem Cell Ther. 13 juin, pp.239-283, 2017.

B. Rambaldi, D. Russo, and L. Pagano, Defining Invasive Fungal Infection Risk in Hematological Malignancies: A New Tool for Clinical Practice, Mediterr J Hematol Infect Dis. 1 janv, vol.9, issue.1, pp.1-4, 2017.

. Société-de-leucémie and C. Lymphome-du,

B. Ko, W. Chen, H. Kung, U. Wu, J. Tang et al., guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan, J Microbiol Immunol Infect, vol.0, issue.0, pp.1-15, 2016.

C. Hahn-ast, L. Felder, K. Mayer, S. Mückter, M. Ruhnke et al., Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia, Ann Hematol. mai, vol.95, issue.6, pp.1001-1010, 2016.

M. M. Ceesay, L. Couchman, M. Smith, J. Wade, R. J. Flanagan et al., Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome, Med Mycol, vol.54, issue.7, pp.691-699, 2016.

J. L. Goodman, D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox et al., A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation, N Engl J Med. 26 mars, vol.326, issue.13, pp.845-51, 1992.

. Vidal-evidal, Fluconazole ARROW 100 mg gél, 2017.

D. Sur,

. Vidal-evidal, Vfend 200 mg cp pelliculé, 2017.

D. Sur,

. Vidal-evidal, Mycamine 100 mg poudre pour solution perfusion, 2017.

D. Sur,

. Vidal-evidal, Itraconazole 100 mg gélule

D. Sur,

F. Tissot, S. Agrawal, L. Pagano, G. Petrikkos, A. H. Groll et al., ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients, Haematologica. 1 mars, vol.102, issue.3, pp.433-477, 2017.

A. Berceanu, S. Lepretre, M. Ojeda-uribe, . Berranger-e-de, . Corda-e-d'incan et al., Prophylaxie antibactérienne et antifongique chez les patients à haut risque en hématologie. Enquête de pratique et forum, Hematologie. 1 janv, vol.17, pp.3-15, 2011.

L. Lewis, C. Padoin, J. Maertens, R. Brüggemann, O. Marchetti et al., ECIL 6 meeting : Triazole Antifungal Therapeutic Drug Monitoring

C. Girmenia, G. Barosi, A. Piciocchi, W. Arcese, F. Aversa et al., Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO), Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. août, vol.20, issue.8, pp.1080-1088, 2014.

S. C. Mellinghoff, J. Panse, N. Alakel, G. Behre, D. Buchheidt et al., Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO), Ann Hematol. 7 déc, pp.197-207, 2017.

J. Gangneux, E. Cheikh, J. Herbrecht, R. Yakoub-agha, I. Caillot et al., Prophylaxie antifongique chez les patients d'hématologie en France : fréquences et choix de l'antifongique systémique en fonction du type d'hémopathie maligne (étude AFHEM), J Mycol Médicale. 1 sept, vol.25, issue.3, pp.225-231, 2015.

J. Zahar, S. Jolivet, H. Adam, C. Dananché, J. Lizon et al., Quelles mesures pour maîtriser le risque infectieux chez les patients immunodéprimés ? Recommandations formalisées d'experts -Journal de Mycologie Médicale, pp.449-56, 2017.

M. Özen, G. Y?lmaz, B. Co?kun, P. Topçuo?lu, B. Öztürk et al., A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction, Turk J Hematol. mars, vol.33, issue.1, pp.41-48, 2016.

A. J. Ullmann, J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston et al., Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med. 25 janv, vol.356, issue.4, pp.335-382, 2007.

L. Pagano, M. Caira, A. Candoni, F. Aversa, C. Castagnola et al., Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry, Clin Infect Dis. 1 déc, vol.55, issue.11, pp.1515-1536, 2012.

O. A. Cornely, J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann et al., Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia, N Engl J Med. 25 janv, vol.356, issue.4, pp.348-59, 2007.

R. Hachem, A. Assaf, Y. Numan, P. Shah, Y. Jiang et al., Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in highrisk patients with hematological malignancies, Int J Antimicrob Agents. 1 sept, vol.50, pp.384-392, 2017.

, Therapie, vol.62, issue.2, pp.115-137, 2010.

. Fda and . Posaconazole, , 2015.

C. Chen, S. Leung, C. Guilbert, M. P. Jacobson, J. H. Mckerrow et al., Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole, PLoS Negl Trop Dis. 6 avr, vol.4, issue.4, pp.1-15, 2010.

. Vidal-evidal, Noxafil 100 mg cp gastrorésis

D. Sur,

S. Alfandari, Actualités des antifongiques systémiques, 2009.

D. Sur, EMEA. Assessment report, 2014.

G. Krishna, L. Ma, M. Martinho, and E. O'mara, Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension, Antimicrob Agents Chemother. août, vol.56, issue.8, pp.4196-201, 2012.

B. Dekkers, M. Bakker, K. Elst, . Van-der, M. Sturkenboom et al., Therapeutic Drug Monitoring of Posaconazole: an Update, Curr Fungal Infect Rep. 1 juin, vol.10, issue.2, pp.51-61, 2016.

R. Fule and P. Amin, Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation, BioMed Res Int, vol.2014, pp.1-16, 2014.

. Vidal-evidal, Noxafil 300 mg sol diluer p perf, 2017.

D. Sur,

D. R. Luke, K. Tomaszewski, B. Damle, and H. T. Schlamm, Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD), J Pharm Sci. août, vol.99, issue.8, pp.3291-301, 2010.

F. Arnaud, Candidose invasive en réanimation, 2015.

D. Allorge and S. Alfandari, Traitements des IFI et suivi thérapeutique pharmacologique -Documents

. C. Docslide and . Br, , 2016.

D. Sur,

H. A. Torres, R. Y. Hachem, R. F. Chemaly, D. P. Kontoyiannis, and I. I. Raad, Posaconazole: a broad-spectrum triazole antifungal, Lancet Infect Dis. déc, vol.5, issue.12, pp.775-85, 2005.

S. Bretagne, Posaconazole : un nouvel antifongique pour quelles indications ?, févr, vol.10, pp.42-51, 2008.

C. M. Martel, J. E. Parker, O. Bader, M. Weig, U. Gross et al., A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14?-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to, Azoles and Amphotericin B. sept, vol.54, issue.9, pp.3578-83, 2010.

W. M. Kersemaekers, P. Dogterom, J. Xu, E. E. Marcantonio, R. De-greef et al., Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation, Antimicrob Agents Chemother, vol.59, issue.6, pp.3385-3394, 2015.

R. Courtney, E. Radwanski, J. Lim, and M. Laughlin, Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men, Antimicrob Agents Chemother. mars, vol.48, issue.3, pp.804-812, 2004.

J. Alffenaar, S. Van-assen, T. S. Van-der-werf, J. Kosterink, and D. Uges, Omeprazole significantly reduces posaconazole serum trough level, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.48, issue.6, p.839, 2009.

M. Sharp, Noxafil 100 mg Gastro-resistant Tablets -Summary of Product Characteristics, 2017.

D. Sur,

A. Petitcollin, C. Boglione-kerrien, C. Tron, S. Nimubona, S. Lalanne et al., Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose, Antimicrob Agents Chemother, vol.61, issue.11, pp.1-25, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01631527

T. Felton, P. F. Troke, and W. W. Hope, Tissue penetration of antifungal agents, Clin Microbiol Rev. janv, vol.27, issue.1, pp.68-88, 2014.

A. Ghosal, N. Hapangama, Y. Yuan, J. Achanfuo-yeboah, R. Iannucci et al., Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil), Drug Metab Dispos Biol Fate Chem. févr, vol.32, issue.2, pp.267-71, 2004.

C. Padoin and O. Tribut, Pharmacocinétique (PK)/ Pharmacodynamie (PD) et place du suivi thérapeutique pharmacologique (STP) des antifongiques, vol.16, pp.329-368, 2010.

S. Seyedmousavi, J. W. Mouton, W. Melchers, R. Brüggemann, and P. E. Verweij, The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside, Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. juill, vol.17, issue.3, pp.37-50, 2014.

S. Seyedmousavi, J. W. Mouton, W. Melchers, and P. E. Verweij, Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis, Antimicrob Agents Chemother. mars, vol.59, issue.3, pp.1487-94, 2015.

G. M. Keating, Posaconazole. Drugs. 1 août, vol.65, issue.11, pp.1553-67, 2005.

A. Petitcollin, R. Crochette, C. Tron, M. Verdier, C. Boglione-kerrien et al., Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole, Drug Metab Pharmacokinet, vol.31, issue.5, pp.389-93, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01376262

I. Sánchez-ortega, L. Vázquez, C. Montes, B. Patiño, M. Arnan et al., Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients, Antimicrob Agents Chemother. déc, vol.56, issue.12, pp.6422-6426, 2012.

, FDA : Noxafil, 2015.

S. Labarde, Enjeux du suivi thérapeutique pharmacologique, Actual Pharm, vol.54, issue.549, pp.39-41, 2015.

K. E. Stott and W. W. Hope, Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations, J Antimicrob Chemother. 1 mars, vol.72, issue.suppl_1, pp.12-20, 2017.

T. J. Walsh, I. Road, T. F. Patterson, P. Chandrasekar, G. R. Donowitz et al., Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial | Clinical Infectious Diseases | Oxford Academic, 2007.

H. R. Ashbee, R. A. Barnes, E. M. Johnson, M. D. Richardson, R. Gorton et al., Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology, J Antimicrob Chemother. 1 mai, vol.69, issue.5, pp.1162-76, 2014.

R. Garraffo and T. Lavrut,

R. K. Shields, C. J. Clancy, A. Vadnerkar, E. J. Kwak, F. P. Silveira et al., Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy, Antimicrob Agents Chemother. mars, vol.55, issue.3, pp.1308-1319, 2011.

O. A. Cornely, R. F. Duarte, S. Haider, P. Chandrasekar, D. Helfgott et al., Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease, J Antimicrob Chemother. mars, vol.71, issue.3, pp.718-744, 2016.

S. H. Jang, P. M. Colangelo, and J. Gobburu, Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma, Clin Pharmacol Ther. juill, vol.88, issue.1, pp.115-124, 2010.

M. Laverdiere, E. J. Bow, C. Rotstein, J. Autmizguine, R. Broady et al., Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective, Can J Infect Dis Med Microbiol, vol.25, issue.6, pp.327-370, 2014.

M. M. Chau, D. Kong, S. J. Van-hal, K. Urbancic, J. A. Trubiano et al., Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, Intern Med J. 1 déc, vol.44, issue.12b, pp.1364-88, 2014.

J. Tonini, A. Thiébaut, J. F. Jourdil, A. S. Berruyer, C. E. Bulabois et al., Therapeutic Drug Monitoring of Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Patients Who Develop Gastrointestinal Graft-versus-Host Disease, Antimicrob Agents Chemother, vol.56, issue.10, pp.5247-52, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00849695

M. J. Dolton, J. E. Ray, S. Chen, K. Ng, L. Pont et al., Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration, Antimicrob Agents Chemother, vol.56, issue.11, pp.5503-5513, 2012.

R. E. Lewis, N. D. Albert, and D. P. Kontoyiannis, Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis, Antimicrob Agents Chemother, vol.58, issue.11, pp.6767-72, 2014.

D. Lebeaux, F. Lanternier, C. Elie, F. Suarez, A. Buzyn et al., Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults, Antimicrob Agents Chemother. déc, vol.53, issue.12, pp.5224-5233, 2009.

S. H. Jang, P. M. Colangelo, and J. Gobburu, Exposure-Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma -Jang -2010 -Clinical Pharmacology & Therapeutics -Wiley Online Library

D. Sur,

D. Andes, A. Pascual, and O. Marchetti, Antifungal therapeutic drug monitoring: established and emerging indications, Antimicrob Agents Chemother. janv, vol.53, issue.1, pp.24-34, 2009.

R. Courtney, S. Pai, M. Laughlin, J. Lim, and V. Batra, Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults, Antimicrob Agents Chemother. sept, vol.47, issue.9, pp.2788-95, 2003.

N. P. Wiederhold, G. J. Pennick, S. A. Dorsey, W. Furmaga, J. S. Lewis et al., A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid, Antimicrob Agents Chemother. 1 janv, vol.58, issue.1, pp.424-455, 2014.

M. J. Dolton, R. Brüggemann, D. M. Burger, and A. J. Mclachlan, Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis, Antimicrob Agents Chemother. 11 janv, vol.58, issue.11, pp.6879-85, 2014.

. Vidal-evidal, Noxafil 40 mg/ml suspension buvable, 2017.

D. Sur,

F. Parant, S. Ducastelle-leprêtre, A. Deloire, M. Michallet, and M. Gagnieu, Nouvelle forme galénique du posaconazole ; Expérience d'un laboratoire hospitalier de pharmacologie, 2016.

R. F. Duarte, J. López-jiménez, O. A. Cornely, M. Laverdiere, D. Helfgott et al., Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia, Antimicrob Agents Chemother. 10 janv, vol.58, issue.10, pp.5758-65, 2014.

G. Krishna, A. Moton, L. Ma, M. M. Medlock, and J. Mcleod, Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers, Antimicrob Agents Chemother. mars, vol.53, issue.3, pp.958-66, 2009.

G. Krishna, L. Ma, D. Vickery, X. Yu, I. Wu et al., Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers, Antimicrob Agents Chemother, vol.53, issue.11, pp.4749-52, 2009.

G. Krishna, M. Abutarif, F. Xuan, M. Martinho, D. Angulo et al., Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome, Pharmacother J Hum Pharmacol Drug Ther, vol.28, issue.10, pp.1223-1255, 2008.

A. N. Pham, J. S. Bubalo, and J. S. Lewis, Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections, Mycoses. 6 janv, pp.226-259, 2016.

A. Cumpston, R. Caddell, A. Shillingburg, X. Lu, S. Wen et al., Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies, Antimicrob Agents Chemother. 8 janv, vol.59, issue.8, pp.4424-4432, 2015.

U. Durani, P. K. Tosh, J. N. Barreto, L. L. Estes, P. J. Jannetto et al., Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension, Antimicrob Agents Chemother. août, vol.59, issue.8, pp.4914-4922, 2015.

M. Belling, A. S. Kanate, A. Shillingburg, X. Lu, S. Wen et al., Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation, Leuk Res Treat, pp.1-6, 2017.

L. A. Tang, B. L. Marini, L. Benitez, J. L. Nagel, M. Miceli et al., Risk factors for subtherapeutic levels of posaconazole tablet, J Antimicrob Chemother, vol.72, issue.10, pp.2902-2907, 2017.

C. Boglione-kerrien, S. Picard, C. Tron, S. Nimubona, J. Gangneux et al., Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies, J Cancer Res Clin Oncol. 20 sept, vol.144, issue.1, pp.127-161, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01685802

E. Leclerc, D. Combarel, M. Uzunov, V. Leblond, C. Funck-brentano et al., Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies, Sci Rep. 26 janv, vol.8, issue.1, pp.1-5, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01708516

F. P. Tverdek, S. T. Heo, S. L. Aitken, B. Granwehr, and D. P. Kontoyiannis, Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses, Antimicrob Agents Chemother. 8 janv, vol.61, issue.8, pp.1-12, 2017.

A. N. Pham, J. S. Bubalo, and J. S. Lewis, Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant, Antimicrob Agents Chemother, vol.60, issue.11, pp.6945-6952, 2016.

M. H. Miceli, A. J. Perissinotti, C. A. Kauffman, and D. R. Couriel, Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis, Mycoses. juill, vol.58, issue.7, pp.432-438, 2015.

W. Kraft, P. Chang, M. V. Iersel, H. Waskin, G. Krishna et al., Effect of Concomitant Medications Affecting Gastric pH and Motility on Posaconazole Tablet Pharmacokinetics, vol.58, pp.4020-4025, 2012.

D. Stelzer, A. Weber, F. Ihle, S. Matthes, F. Ceelen et al., Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability, Ther Drug Monit. avr, vol.39, issue.2, pp.93-101, 2017.

D. S. Jung, F. P. Tverdek, and D. P. Kontoyiannis, Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity, Antimicrob Agents Chemother, vol.58, issue.11, pp.6993-6998, 2014.

B. Bégaud, J. C. Evreux, J. Jouglard, and G. Lagier,

, Therapie. avr, vol.40, issue.2, pp.111-119, 1985.

I. Kyriakidis, A. Tragiannidis, S. Munchen, and A. H. Groll, Clinical hepatotoxicity associated with antifungal agents, Expert Opin Drug Saf. 1 févr, vol.16, issue.2, pp.149-65, 2017.

N. N. Petit, J. L. Steinback, Z. Han, J. De-la-cruz, L. E. Pisano et al., Posaconazole tablet formulation therapeutic drug monitoring and toxicity analysis, Poster presented at 54th Interscience conference on antimicrobial agents and chemotherapy, pp.5-9, 2014.

H. Ghnaya, Cours Hématologie UE 2.9 S5 C4, 2017.

D. Sur,

, Cancer Research Group. ECOG Performance Status

. Ecog-acrin, , p.24, 2017.

, Annexe 2 Première différenciation d'une cellule souche totipotente (119)